Source link : https://www.newshealth.biz/health-news/arpis-beneficial-in-prostate-cancer/
TOPLINE: In patients with prostate cancer, androgen receptor pathway inhibitors (ARPIs) extended the median time to no longer clinically benefitting (NLCB) to 11.1 months vs the 6.9 months seen with taxanes. Overall survival was also higher for those taking ARPIs than for those taking taxanes, in the randomized controlled trial. METHODOLOGY: Researchers conducted an outcome-adaptive […]
Author : News Health
Publish date : 2024-09-05 05:41:42
Copyright for syndicated content belongs to the linked Source.